SCHEMBL5197183

SCHEMBL5197183

CON(C)CCN(C1CCCCC1)C1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2)NC2CCN(C(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
HTT P42858 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NR1D1 P20393 1/20 0.40
STS P08842 2/20 0.40
MAPK1 P28482 2/20 0.39
GPR119 Q8TDV5 2/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MC4R P32245 4/20 0.39
EPHX1 P07099 1/20 0.39
YAP1 P46937 2/20 0.39
MC5R P33032 2/20 0.39
MC3R P41968 2/20 0.39
MC1R Q01726 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5370825 0.89 MC4R (0.40) MEN1KMT2AHTTALDH1A1MC4R
SCHEMBL5444005 0.88 MC4R (0.42) MC4RMC5RMC3RMC1R
Hydrochloric Acid SCHEMBL5458137 0.87 MC4R (0.42) MC4RMC5RMC3RMC1R
SCHEMBL5449611 0.86 GPR119 (0.42) MEN1KMT2AHTTSMN1; SMN2NPSR1
SCHEMBL5449383 0.85 MEN1 (0.44) MEN1KMT2AHTTSMN1; SMN2NPSR1
SCHEMBL5199301 0.84 ALDH1A1 (0.47) MEN1KMT2AHTTSMN1; SMN2NPSR1
SCHEMBL5449365 0.84 MC4R (0.42) MEN1KMT2AHTTSMN1; SMN2NPSR1
SCHEMBL5451925 0.80 EPHX1 (0.49) MEN1KMT2AGPR119ALDH1A1EPHX1
SCHEMBL655029 0.79 YAP1 (0.54) MEN1KMT2AHTTSMN1; SMN2NPSR1
SCHEMBL3147740 0.79 YAP1 (0.54) MEN1KMT2AHTTSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191364-A1 AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-08-16 US disclosed
EP-1786809-A2 AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONISTS Sanofi-Aventis (FR) 2007-05-23 EP disclosed
WO-2006021656-A2 AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS MELANOCORTIN RECEPTOR AGONISTS SANOFI-AVENTIS (FR) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191364-A1 AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF MC4R, MC5R, TAAR5 MEN1 1307/4885KMT2A 1421/4885HTT 2683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.